Activating transcription factor 3, glucolipid metabolism, and metabolic diseases. (6th December 2022)

• Record Type: Journal Article
• Authors: Hu, Shuwei; Zhao, Xiaojie; Li, Rui; Hu, Chencheng; Wu, Huijuan; Li, Jing; Zhang, Yanqiao; Xu, Yanyong
• Editors: Jia, Wei-Ping
• Is Part Of: Journal of molecular cell biology. Volume 14:Number 10(2022)
• Publication Date: 2022-12-06
• Subjects: ATF3 -- glucolipid metabolism -- metabolic organ -- metabolic diseases; Molecular biology -- Periodicals; 571.605
• DOI: 10.1093/jmcb/mjac067
• Languages: English
• ISSNs: 1674-2788

Abstract

ABSTRACT: Lipids and glucose exert many essential physiological functions, such as providing raw materials or energy for cellular biosynthesis, regulating cell signal transduction, and maintaining a constant body temperature. Dysregulation of lipid and glucose metabolism can lead to glucolipid metabolic disorders linked to various metabolic diseases, such as obesity, diabetes, and cardiovascular disease. Therefore, intervention in glucolipid metabolism is a key therapeutic strategy for the treatment of metabolic diseases. Activating transcription factor 3 (ATF3) is a transcription factor that acts as a hub of the cellular adaptive-response network and plays a pivotal role in the regulation of inflammation, apoptosis, DNA repair, and oncogenesis. Emerging evidence has illustrated the vital roles of ATF3 in glucolipid metabolism. ATF3 inhibits intestinal lipid absorption, enhances hepatic triglyceride hydrolysis and fatty acid oxidation, promotes macrophage reverse cholesterol transport, and attenuates the progression of western diet-induced nonalcoholic fatty liver disease and atherosclerosis. In addition to its role in lipid metabolism, ATF3 has also been identified as an important regulator of glucose metabolism. Here, we summarize the recent advances in the understanding of ATF3, mainly focusing on its role in glucose and lipid metabolism and potential therapeutic implications. Graphical Abstract: